{"protocolSection": {"identificationModule": {"nctId": "NCT00680745", "orgStudyIdInfo": {"id": "D1690C00005"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients", "officialTitle": "A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone"}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-05-16", "studyFirstSubmitQcDate": "2008-05-19", "studyFirstPostDateStruct": {"date": "2008-05-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-13", "resultsFirstSubmitQcDate": "2013-08-09", "resultsFirstPostDateStruct": {"date": "2013-10-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-08-09", "lastUpdatePostDateStruct": {"date": "2013-10-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["Dapagliflozin", "efficacy", "safety", "sulphonylurea", "Type 2 diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 597, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "dapagliflozin 2.5mg + Glimepiride", "interventionNames": ["Drug: dapagliflozin", "Drug: Glimepiride", "Drug: metformin hydrochloride", "Drug: pioglitazone hydrochloride", "Drug: Rosiglitazone"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "dapagliflozin 5mg + Glimepiride", "interventionNames": ["Drug: dapagliflozin", "Drug: Glimepiride", "Drug: metformin hydrochloride", "Drug: pioglitazone hydrochloride", "Drug: Rosiglitazone"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "dapagliflozin 10mg + Glimepiride", "interventionNames": ["Drug: dapagliflozin", "Drug: Glimepiride", "Drug: metformin hydrochloride", "Drug: pioglitazone hydrochloride", "Drug: Rosiglitazone"]}, {"label": "4", "type": "PLACEBO_COMPARATOR", "description": "Placebo + Glimepiride", "interventionNames": ["Drug: Glimepiride", "Drug: metformin hydrochloride", "Drug: pioglitazone hydrochloride", "Drug: Rosiglitazone"]}], "interventions": [{"type": "DRUG", "name": "dapagliflozin", "description": "tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks", "armGroupLabels": ["1", "2", "3"]}, {"type": "DRUG", "name": "Glimepiride", "description": "tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks", "armGroupLabels": ["1", "2", "3", "4"], "otherNames": ["Amaryl"]}, {"type": "DRUG", "name": "metformin hydrochloride", "description": "rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice", "armGroupLabels": ["1", "2", "3", "4"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "pioglitazone hydrochloride", "description": "rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice", "armGroupLabels": ["1", "2", "3", "4"], "otherNames": ["Actos"]}, {"type": "DRUG", "name": "Rosiglitazone", "description": "rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice", "armGroupLabels": ["1", "2", "3", "4"], "otherNames": ["Avandia"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change in HbA1c Levels", "description": "To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period.", "timeFrame": "Baseline to Week 24"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change in Body Weight", "description": "To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride.", "timeFrame": "Baseline to Week 24"}, {"measure": "Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise", "description": "To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24.", "timeFrame": "Baseline to Week 24"}, {"measure": "Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%", "description": "To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c \\< 7% after 24 weeks of treatment, compared to placebo plus glimepiride.", "timeFrame": "At Week 24"}, {"measure": "Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)\u226527 kg/m2", "description": "To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI \u226527 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride.", "timeFrame": "Baseline to Week 24"}, {"measure": "Adjusted Mean Change in Fasting Plasma Glucose (FPG)", "description": "To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride.", "timeFrame": "Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 Diabetes\n* Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study\n* Inadequate glycaemic control, defined as A1C \u2265 7.0 % and \u2264 10%\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Hepatic (liver) impairment\n* Renal (kidney) failure or dysfunction", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Krzysztof Strojek, Prof. Dr.", "affiliation": "Silesian Medical University3-Maja 13/15, 41-800 Zabrze; Poland", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Blansko", "country": "Czech Republic", "geoPoint": {"lat": 49.36304, "lon": 16.64446}}, {"facility": "Research Site", "city": "Breclav", "country": "Czech Republic", "geoPoint": {"lat": 48.75897, "lon": 16.88203}}, {"facility": "Research Site", "city": "Bruntal", "country": "Czech Republic", "geoPoint": {"lat": 49.98844, "lon": 17.4647}}, {"facility": "Research Site", "city": "Hodonin", "country": "Czech Republic", "geoPoint": {"lat": 48.84893, "lon": 17.13244}}, {"facility": "Research Site", "city": "Ostrava - Belsky Les", "country": "Czech Republic", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"facility": "Research Site", "city": "Plzen", "country": "Czech Republic", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Research Site", "city": "Praha 1", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Pribram Viii", "country": "Czech Republic"}, {"facility": "Research Site", "city": "Rakovnik", "country": "Czech Republic", "geoPoint": {"lat": 50.1037, "lon": 13.7334}}, {"facility": "Research Site", "city": "Semily", "country": "Czech Republic", "geoPoint": {"lat": 50.60191, "lon": 15.33552}}, {"facility": "Research Site", "city": "Balatonfured", "country": "Hungary", "geoPoint": {"lat": 46.96188, "lon": 17.87187}}, {"facility": "Research Site", "city": "Bekescsaba", "country": "Hungary", "geoPoint": {"lat": 46.68333, "lon": 21.1}}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Csongrad", "country": "Hungary", "geoPoint": {"lat": 46.71332, "lon": 20.14241}}, {"facility": "Research Site", "city": "Eger", "country": "Hungary", "geoPoint": {"lat": 47.90265, "lon": 20.37329}}, {"facility": "Research Site", "city": "Gyongyos", "country": "Hungary", "geoPoint": {"lat": 47.78257, "lon": 19.928}}, {"facility": "Research Site", "city": "Kecskemet", "country": "Hungary", "geoPoint": {"lat": 46.90618, "lon": 19.69128}}, {"facility": "Research Site", "city": "Mako", "country": "Hungary", "geoPoint": {"lat": 46.21667, "lon": 20.48333}}, {"facility": "Research Site", "city": "Miskolc", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Research Site", "city": "Mosonmagyarovar", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Research Site", "city": "Siofok", "country": "Hungary", "geoPoint": {"lat": 46.90413, "lon": 18.058}}, {"facility": "Research Site", "city": "Szentes", "country": "Hungary", "geoPoint": {"lat": 46.65628, "lon": 20.27194}}, {"facility": "Research Site", "city": "TAT", "country": "Hungary", "geoPoint": {"lat": 47.74148, "lon": 18.64813}}, {"facility": "Research Site", "city": "Zalaegerszeg", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"facility": "Research Site", "city": "Jeonju", "state": "Chonbuk", "country": "Korea, Republic of", "geoPoint": {"lat": 35.82194, "lon": 127.14889}}, {"facility": "Research Site", "city": "Wonju", "state": "Kangwon-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.35139, "lon": 127.94528}}, {"facility": "Research Site", "city": "Suwon", "state": "Kyunggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Bucheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research Site", "city": "Seongnam", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Uljeongbu", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Cebu City", "country": "Philippines", "geoPoint": {"lat": 10.31672, "lon": 123.89071}}, {"facility": "Research Site", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Research Site", "city": "Marikina City", "country": "Philippines", "geoPoint": {"lat": 14.6481, "lon": 121.1133}}, {"facility": "Research Site", "city": "Pasig City", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Research Site", "city": "Bielsko - Biala", "country": "Poland", "geoPoint": {"lat": 49.82245, "lon": 19.04686}}, {"facility": "Research Site", "city": "Bydgoszcz", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Chojnice", "country": "Poland", "geoPoint": {"lat": 53.69554, "lon": 17.55701}}, {"facility": "Research Site", "city": "Chrzanow", "country": "Poland", "geoPoint": {"lat": 50.13546, "lon": 19.40203}}, {"facility": "Research Site", "city": "Ciechocinek", "country": "Poland", "geoPoint": {"lat": 52.87908, "lon": 18.79505}}, {"facility": "Research Site", "city": "Czechowice-Dziedzice", "country": "Poland", "geoPoint": {"lat": 49.91342, "lon": 19.00479}}, {"facility": "Research Site", "city": "Elblag", "country": "Poland", "geoPoint": {"lat": 54.1522, "lon": 19.40884}}, {"facility": "Research Site", "city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Gniewkowo", "country": "Poland", "geoPoint": {"lat": 52.89461, "lon": 18.40785}}, {"facility": "Research Site", "city": "Grudziadz", "country": "Poland", "geoPoint": {"lat": 53.48411, "lon": 18.75366}}, {"facility": "Research Site", "city": "Ilawa", "country": "Poland", "geoPoint": {"lat": 53.59601, "lon": 19.56849}}, {"facility": "Research Site", "city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Mragowo", "country": "Poland", "geoPoint": {"lat": 53.86437, "lon": 21.30507}}, {"facility": "Research Site", "city": "Plock", "country": "Poland", "geoPoint": {"lat": 52.54682, "lon": 19.70638}}, {"facility": "Research Site", "city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Ruda Slaska", "country": "Poland", "geoPoint": {"lat": 50.2584, "lon": 18.85632}}, {"facility": "Research Site", "city": "Sopot", "country": "Poland", "geoPoint": {"lat": 54.4418, "lon": 18.56003}}, {"facility": "Research Site", "city": "Torun", "country": "Poland", "geoPoint": {"lat": 53.01375, "lon": 18.59814}}, {"facility": "Research Site", "city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Zabrze", "country": "Poland", "geoPoint": {"lat": 50.32492, "lon": 18.78576}}, {"facility": "Research Site", "city": "Zielona Gora", "country": "Poland", "geoPoint": {"lat": 51.93548, "lon": 15.50643}}, {"facility": "Research Site", "city": "Zory", "country": "Poland", "geoPoint": {"lat": 50.04523, "lon": 18.70062}}, {"facility": "Research Site", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Research Site", "city": "Chiang Mai", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"facility": "Research Site", "city": "Dnipropetrov'sk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Research Site", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Research Site", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Vinnytsia", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Research Site", "city": "Zaporozhye", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}]}, "referencesModule": {"references": [{"pmid": "33368935", "type": "DERIVED", "citation": "Shah M, Stolbov L, Yakovleva T, Tang W, Sokolov V, Penland RC, Boulton D, Parkinson J. A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes Obes Metab. 2021 Apr;23(4):991-1000. doi: 10.1111/dom.14305. Epub 2021 Jan 25."}, {"pmid": "23529567", "type": "DERIVED", "citation": "Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride]. Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S16-26. doi: 10.1055/s-0032-1305277. Epub 2013 Mar 25. German."}, {"pmid": "21672123", "type": "DERIVED", "citation": "Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011 Oct;13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Reasons for enrolled participants not being randomised: 229 incorrect enrollment, 4 adverse event, 23 withdrew consent, 2 lost to follow up and 4 other.", "recruitmentDetails": "Enrollment: 859 (597 randomized and 592 in the Full Analysis Set) Study Start Date:April 2008 Study Completion Date:May 2010 Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)", "groups": [{"id": "FG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "FG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "FG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "FG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Safety Analysis Set", "numSubjects": "154"}, {"groupId": "FG001", "comment": "Safety Analysis Set", "numSubjects": "145"}, {"groupId": "FG002", "comment": "Safety Analysis Set", "numSubjects": "151"}, {"groupId": "FG003", "comment": "Safety Analysis Set", "numSubjects": "146"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "140"}, {"groupId": "FG001", "numSubjects": "132"}, {"groupId": "FG002", "numSubjects": "141"}, {"groupId": "FG003", "numSubjects": "133"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Poor/Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Subject No Longer Meets Study Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "False Treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.", "groups": [{"id": "BG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "BG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "BG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "BG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "154"}, {"groupId": "BG001", "value": "142"}, {"groupId": "BG002", "value": "151"}, {"groupId": "BG003", "value": "145"}, {"groupId": "BG004", "value": "592"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.9", "spread": "10.14"}, {"groupId": "BG001", "value": "60.2", "spread": "9.73"}, {"groupId": "BG002", "value": "58.9", "spread": "8.32"}, {"groupId": "BG003", "value": "60.3", "spread": "10.16"}, {"groupId": "BG004", "value": "59.8", "spread": "9.60"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "85"}, {"groupId": "BG003", "value": "74"}, {"groupId": "BG004", "value": "307"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "66"}, {"groupId": "BG003", "value": "71"}, {"groupId": "BG004", "value": "285"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "106"}, {"groupId": "BG003", "value": "101"}, {"groupId": "BG004", "value": "411"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "44"}, {"groupId": "BG004", "value": "181"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.01", "spread": "5.120"}, {"groupId": "BG001", "value": "29.84", "spread": "5.182"}, {"groupId": "BG002", "value": "29.75", "spread": "5.641"}, {"groupId": "BG003", "value": "29.74", "spread": "4.569"}, {"groupId": "BG004", "value": "29.84", "spread": "5.135"}]}]}]}, {"title": "HbA1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.11", "spread": "0.749"}, {"groupId": "BG001", "value": "8.12", "spread": "0.781"}, {"groupId": "BG002", "value": "8.07", "spread": "0.790"}, {"groupId": "BG003", "value": "8.15", "spread": "0.736"}, {"groupId": "BG004", "value": "8.11", "spread": "0.763"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change in HbA1c Levels", "description": "To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "OG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "142"}, {"groupId": "OG002", "value": "150"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "lowerLimit": "-0.69", "upperLimit": "-0.46"}, {"groupId": "OG001", "value": "-0.63", "lowerLimit": "-0.75", "upperLimit": "-0.50"}, {"groupId": "OG002", "value": "-0.82", "lowerLimit": "-0.94", "upperLimit": "-0.70"}, {"groupId": "OG003", "value": "-0.13", "lowerLimit": "-0.26", "upperLimit": "-0.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.019 applying Dunnett's adjustment, two-sided)", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.019 (2-sided) applying Dunnett's adjustment. A hierarchical closed testing procedure was used to control the Type I error rate across the primary and key secondary endpoints.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.61", "ciUpperLimit": "-0.27", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0867"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.019 applying Dunnett's adjustment, two-sided).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.019 (2-sided) applying Dunnett's adjustment. A hierarchical closed testing procedure was used to control the Type I error rate across the primary and key secondary endpoints.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.67", "ciUpperLimit": "-0.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0885"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0 (with alpha = 0.019 applying Dunnett's adjustment, two-sided).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.019 (2-sided) applying Dunnett's adjustment. A hierarchical closed testing procedure was used to control the Type I error rate across the primary and key secondary endpoints.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.86", "ciUpperLimit": "-0.51", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0873"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in Body Weight", "description": "To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "OG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "OG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "142"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.18", "lowerLimit": "-1.62", "upperLimit": "-0.75"}, {"groupId": "OG001", "value": "-1.56", "lowerLimit": "-2.01", "upperLimit": "-1.11"}, {"groupId": "OG002", "value": "-2.26", "lowerLimit": "-2.70", "upperLimit": "-1.83"}, {"groupId": "OG003", "value": "-0.72", "lowerLimit": "-1.16", "upperLimit": "-0.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1410", "pValueComment": "not significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.08", "ciUpperLimit": "0.15", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3153"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0091", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.47", "ciUpperLimit": "-0.21", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3217"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.17", "ciUpperLimit": "-0.92", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3168"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise", "description": "To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "OG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "OG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "117"}, {"groupId": "OG002", "value": "132"}, {"groupId": "OG003", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.5", "lowerLimit": "-46.7", "upperLimit": "-28.3"}, {"groupId": "OG001", "value": "-32.0", "lowerLimit": "-41.5", "upperLimit": "-22.5"}, {"groupId": "OG002", "value": "-34.9", "lowerLimit": "-43.8", "upperLimit": "-25.9"}, {"groupId": "OG003", "value": "-6.0", "lowerLimit": "-15.8", "upperLimit": "3.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Not significant. Hierarchical closed testing procedure within treatment group stopped at previous endpoint.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-31.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-45.0", "ciUpperLimit": "-18.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.874"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-26.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.7", "ciUpperLimit": "-12.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.968"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-28.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-42.2", "ciUpperLimit": "-15.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.770"}]}, {"type": "SECONDARY", "title": "Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%", "description": "To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c \\< 7% after 24 weeks of treatment, compared to placebo plus glimepiride.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "At Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "OG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "OG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "142"}, {"groupId": "OG002", "value": "150"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.8", "lowerLimit": "20.2", "upperLimit": "33.3"}, {"groupId": "OG001", "value": "30.3", "lowerLimit": "23.4", "upperLimit": "37.1"}, {"groupId": "OG002", "value": "31.7", "lowerLimit": "24.7", "upperLimit": "38.7"}, {"groupId": "OG003", "value": "13.0", "lowerLimit": "7.6", "upperLimit": "18.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Not significant. Hierarchical closed testing procedure within treatment group stopped at previous endpoint.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Based on methodology of Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu, with adjustment for baseline value.", "paramType": "Risk Difference (RD)", "paramValue": "13.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.4", "ciUpperLimit": "22.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.265"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Based on methodology of Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu, with adjustment for baseline value.", "paramType": "Risk Difference (RD)", "paramValue": "17.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.7", "ciUpperLimit": "25.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.392"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Based on methodology of Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu, with adjustment for baseline value.", "paramType": "Risk Difference (RD)", "paramValue": "18.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.9", "ciUpperLimit": "27.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.457"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)\u226527 kg/m2", "description": "To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI \u226527 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride.", "populationDescription": "Full Analysis Set, participants with baseline BMI of 27 kg/m2 or more and Week 24 (LOCF) body weight value", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "OG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "OG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "97"}, {"groupId": "OG002", "value": "99"}, {"groupId": "OG003", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.17", "lowerLimit": "-1.75", "upperLimit": "-0.59"}, {"groupId": "OG001", "value": "-1.74", "lowerLimit": "-2.34", "upperLimit": "-1.15"}, {"groupId": "OG002", "value": "-2.47", "lowerLimit": "-3.06", "upperLimit": "-1.88"}, {"groupId": "OG003", "value": "-0.80", "lowerLimit": "-1.38", "upperLimit": "-0.22"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Not significant. Hierarchical closed testing procedure within treatment group stopped at previous endpoint.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.19", "ciUpperLimit": "0.45", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4159"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0262", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.78", "ciUpperLimit": "-0.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4234"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.67", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.50", "ciUpperLimit": "-0.84", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4211"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in Fasting Plasma Glucose (FPG)", "description": "To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride"}, {"id": "OG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride"}, {"id": "OG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride"}, {"id": "OG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "142"}, {"groupId": "OG002", "value": "150"}, {"groupId": "OG003", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.8", "lowerLimit": "-21.7", "upperLimit": "-12.0"}, {"groupId": "OG001", "value": "-21.2", "lowerLimit": "-26.3", "upperLimit": "-16.2"}, {"groupId": "OG002", "value": "-28.5", "lowerLimit": "-33.4", "upperLimit": "-23.6"}, {"groupId": "OG003", "value": "-2.0", "lowerLimit": "-6.9", "upperLimit": "3.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Not significant. Hierarchical closed testing procedure within treatment group stopped at previous endpoint.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-14.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.8", "ciUpperLimit": "-7.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.522"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.3", "ciUpperLimit": "-12.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.594"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "The null hypothesis is given as H0: mean(treat) minus mean(placebo) = 0 versus HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "significant at alpha=0.05 (2-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure within treatment group.", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group as effect (all treatment groups included) and baseline value as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-26.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.5", "ciUpperLimit": "-19.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.545"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Non-serious/serious adverse events on or after the first day and on or prior to the last day of the 24-week double-blind treatment period plus 4/30 days or up to follow-up visit if earlier, or up to and incl the start date of extension period if earlier.", "description": "Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin 2.5mg + Glimepiride", "description": "Dapagliflozin tablet 2.5 mg once daily plus glimepiride", "seriousNumAffected": 11, "seriousNumAtRisk": 154, "otherNumAffected": 22, "otherNumAtRisk": 154}, {"id": "EG001", "title": "Dapagliflozin 5mg + Glimepiride", "description": "Dapagliflozin tablet 5 mg once daily plus glimepiride", "seriousNumAffected": 10, "seriousNumAtRisk": 145, "otherNumAffected": 19, "otherNumAtRisk": 145}, {"id": "EG002", "title": "Dapagliflozin 10mg + Glimepiride", "description": "Dapagliflozin tablet 10 mg once daily plus glimepiride", "seriousNumAffected": 9, "seriousNumAtRisk": 151, "otherNumAffected": 18, "otherNumAtRisk": 151}, {"id": "EG003", "title": "Placebo + Glimepiride", "description": "Placebo comparator plus glimepiride", "seriousNumAffected": 7, "seriousNumAtRisk": 146, "otherNumAffected": 15, "otherNumAtRisk": 146}], "seriousEvents": [{"term": "Febrile Neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "ANGINA PECTORIS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "AORTIC VALVE DISEASE MIXED", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "ATRIOVENTRICULAR BLOCK COMPLETE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "CARDIAC FAILURE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "CARDIO-RESPIRATORY ARREST", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "CORONARY ARTERY STENOSIS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "SUPRAVENTRICULAR TACHYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "VERTIGO", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "GASTRODUODENITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "NON-CARDIAC CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "CHOLECYSTITIS ACUTE", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "CHOLELITHIASIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "MULTIPLE ALLERGIES", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "HAND FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "JOINT DISLOCATION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "OVERDOSE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "DIABETES MELLITUS", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "OBESITY", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "ARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "NECK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "ROTATOR CUFF SYNDROME", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "SPINAL COLUMN STENOSIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "BENIGN BREAST NEOPLASM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "CHRONIC LYMPHOCYTIC LEUKAEMIA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "LUNG NEOPLASM MALIGNANT", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "RECTAL ADENOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "CEREBROVASCULAR ACCIDENT", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "TRANSIENT ISCHAEMIC ATTACK", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "RENAL COLIC", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "UTERINE POLYP", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "PNEUMOTHORAX", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "PULMONARY EMBOLISM", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}, {"term": "PULMONARY OEDEMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 146}]}, {"term": "DEEP VEIN THROMBOSIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 146}]}], "otherEvents": [{"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 146}]}, {"term": "HYPERTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 146}]}, {"term": "Hypoglycemia", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 154}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 146}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to rescue medication were used."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications."}, "pointOfContact": {"title": "Eva Johnsson", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["India"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000077154", "term": "Rosiglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Facial", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Psoriasis Vulgaris", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M1677", "name": "Rosiglitazone", "asFound": "Facility", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}]}}, "hasResults": true}